Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials

References

• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. 2017 The hormone therapy position statement of The North American Menopause Society. Menopause 2017;24:728–53
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978
   PubMedGoogle Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014;123:202–16
   PubMed Web of Science ®Google Scholar
• Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor symptoms. J Br Menopause Soc 2006;12:7–11
   PubMedGoogle Scholar
• Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010;CD004923
   PubMed Web of Science ®Google Scholar
• Winokur A, DeMartinis NA, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003;64:1224–9
   PubMed Web of Science ®Google Scholar
• Ivgy-May N, Roth T, Ruwe F, et al. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial. Sleep Med 2015;16:831–7
   PubMed Web of Science ®Google Scholar
• Enomoto T, Yamashita A, Torigoe K, et al. Effects of mirtazapine on sleep disturbance under neuropathic pain-like state. Synapse 2012;66:483–8
   PubMed Web of Science ®Google Scholar
• Berendsen HHG, Kloosterboer HJ. Oestradiol and mirtazapine restore the disturbed tail-temperature of oestrogen-deficient rats. Eur J Pharmacol 2003;482:329–33
   PubMed Web of Science ®Google Scholar
• Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004;2:50–6
   PubMedGoogle Scholar
• Biglia N, Kubatzki F, Sgandurra P, et al. Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. Breast J 2007;13:490–5
   PubMed Web of Science ®Google Scholar
• Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027–35
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000;38:461–74
   PubMed Web of Science ®Google Scholar
• Alfaro CL, Lam YWF, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000;40:58–66
   PubMed Web of Science ®Google Scholar
• Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688–97
   PubMed Web of Science ®Google Scholar
• Binkhorst L, Mathijssen RHJ, van Herk-Sukel MPP, et al. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat 2013;139:923–9
   PubMed Web of Science ®Google Scholar
• Guttuso T, Jr., Kurlan R, McDermott MP, et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337–45
   PubMed Web of Science ®Google Scholar
• Singhal SR, Shullai WK. Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms. J Midlife Health 2016;7:132–9
   PubMedGoogle Scholar
• Butt DA, Lock M, Lewis JE, et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15:310–18
   PubMed Web of Science ®Google Scholar
• Ivgy-May N, Ruwe F, Krystal A, et al. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. Sleep Med 2015;16:838–44
   PubMed Web of Science ®Google Scholar
• Ruwe F, Ivgy-May N, IJzerman-Boon P, et al. A Phase II randomized, 4-way cross-over, double-blind, placebo-controlled, multicenter dose-finding trial with esmirtazapine in patients with primary insomnia. [Abstract]. Sleep 2012;35:A224
   Web of Science ®Google Scholar
• Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259–66
   PubMed Web of Science ®Google Scholar
• Nateri NS, Beigi M, Kazemi A, et al. Women coping strategies towards menopause and its relationship with sexual dysfunction. Iran J Nurs Midwifery Res 2017;22:343–7
   PubMedGoogle Scholar
• Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267–85
   PubMed Web of Science ®Google Scholar
• Chiu H-W, Li T-C. Rapid weight gain during mirtazapine treatment. J Neuropsychiatry Clin Neurosci 2011;23:E7
   PubMed Web of Science ®Google Scholar
• Yao S, Li J, Fan X, et al. The effect of selective serotonin re-uptake inhibitors on risk of type II diabetes mellitus and acute pancreatitis: a meta-analysis. Biosci Rep 2018;38:BSR20180967
   PubMed Web of Science ®Google Scholar
• Cheng Y, Hu H, Lin X, et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan. Medicine 2015;94:e2022
   PubMed Web of Science ®Google Scholar
• Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int 2014;25:1473–81
   PubMed Web of Science ®Google Scholar
• Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792–8
   PubMed Web of Science ®Google Scholar
• Shively CA, Register TC, Appt SE, et al. Effects of long-term sertraline treatment and depression on coronary artery atherosclerosis in premenopausal female primates. Psychosom Med 2015;77:267–78
   PubMed Web of Science ®Google Scholar
• Silverstein-Metzler MG, Justice JN, Appt SE, et al. Long-term sertraline treatment and depression effects on carotid artery atherosclerosis in premenopausal female primates. Menopause 2017;24:1175–84
   PubMed Web of Science ®Google Scholar
• Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880
   PubMed Web of Science ®Google Scholar